ARHGEF19 promotes the growth of breast cancer in vitro and in vivo by the MAPK pathway.

Objective To assess the expression of ARHGEF19 in human breast cancer, investigate its role in breast cancer, and clarify the mechanism. Methods Bioinformatics analysis, immunoblot, quantitative PCR, and immunohistochemical (IHC) assays were performed to assess ARHGEF19 expression in breast cancer. CCK-8 and Edu assays were conducted to reveal its role in breast cancer cell proliferation. Flow cytometry (FCM) assays and immunoblot were performed to confirm its effects on breast cancer apoptosis. Immunoblot was also performed to clarify the mechanism. Finally, tumor growth assays were aimed to confirm the role of ARHGEF19 in mice. Results We observed that ARHGEF19 was highly expressed in human breast cancer. ARHGEF19 promoted breast cancer cell growth in vitro, and suppressed apoptosis. In addition, we found that ARHGEF19 could activate the MAPK pathway in breast cancer cells. Our findings further confirmed that ARHGEF19 contributed to breast cancer growth in mice. Conclusion We observed that ARHGEF19 promoted the growth of breast cancer in vitro and in vivo via MAPK pathway, and presume it could serve as a breast cancer therapeutic target.

[1]  L. Galluzzi,et al.  Immunological barriers to immunotherapy in primary and metastatic breast cancer , 2021, EMBO molecular medicine.

[2]  M. Koizumi,et al.  Chk1 suppression leads to a reduction in the enhanced radiation-induced invasive capability on breast cancer cells , 2021, Journal of radiation research.

[3]  K. Cui,et al.  A panel of 8-lncRNA predicts prognosis of breast cancer patients and migration of breast cancer cells , 2021, PloS one.

[4]  Huajun Zhao,et al.  F1012-2 Induced ROS-Mediated DNA Damage Response through Activation of MAPK Pathway in Triple-Negative Breast Cancer , 2021, BioMed research international.

[5]  Xin Liu,et al.  Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms , 2021, Frontiers in Oncology.

[6]  Y. Haldorai,et al.  Synergistic Effect of Photothermally Targeted NIR-Responsive Nanomedicine-Induced Immunogenic Cell Death for Effective Triple Negative Breast Cancer Therapy. , 2021, Biomacromolecules.

[7]  Shile Huang,et al.  Metformin prevents BAFF activation of Erk1/2 from B-cell proliferation and survival by impeding mTOR-PTEN/Akt signaling pathway. , 2021, International immunopharmacology.

[8]  S. Reddy,et al.  New horizons in imaging and surgical assessment of breast cancer lymph node metastasis , 2021, Breast Cancer Research and Treatment.

[9]  Fan Jia,et al.  Multicomponent-assembled nanodiamond hybrids for targeted and imaging guided triple-negative breast cancer therapy via a ternary collaborative strategy. , 2021, Biomaterials science.

[10]  A. Khan,et al.  Redox-responsive hyaluronic acid-based nanoparticles for targeted photodynamic therapy/chemotherapy against breast cancer. , 2021, Journal of colloid and interface science.

[11]  Liying Zhang,et al.  How do patient-reported outcomes compare with clinician assessments? A prospective study of radiation dermatitis in breast cancer. , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  Wen Li,et al.  IL-33/ST2 promotes the malignant progression of gastric cancer via the MAPK pathway , 2021, Molecular medicine reports.

[13]  A. Tiwari,et al.  Biomimetic Microfluidic Platforms for the Assessment of Breast Cancer Metastasis , 2021, Frontiers in Bioengineering and Biotechnology.

[14]  S. Dharmawardhane.  Rho Family GTPases in Cancer , 2021, Cancers.

[15]  Xiaoyan Li,et al.  RNA-binding protein QKI suppresses breast cancer via RASA1/MAPK signaling pathway , 2021, Annals of translational medicine.

[16]  P. Zeng,et al.  Improved Detection of Potentially Pleiotropic Genes in Coronary Artery Disease and Chronic Kidney Disease Using GWAS Summary Statistics , 2020, Frontiers in Genetics.

[17]  S. Moriya,et al.  Regulation of Oncogenic Targets by the Tumor-Suppressive miR-139 Duplex (miR-139-5p and miR-139-3p) in Renal Cell Carcinoma , 2020, Biomedicines.

[18]  Chunjie Sheng,et al.  ARHGEF19 regulates MAPK/ERK signaling and promotes the progression of small cell lung cancer. , 2020, Biochemical and biophysical research communications.

[19]  Wenjie Zhao,et al.  MicroRNA-126 exerts antitumor functions in ovarian cancer by targeting EGFL7 and affecting epithelial-to-mesenchymal transition and ERK/MAPK signaling pathway , 2020, Oncology letters.

[20]  T. Lecuit,et al.  Distinct RhoGEFs Activate Apical and Junctional Contractility under Control of G Proteins during Epithelial Morphogenesis , 2019, Current Biology.

[21]  M. Kloc,et al.  Divergent roles of the Wnt/PCP Formin Daam1 in renal ciliogenesis , 2019, PloS one.

[22]  C. Brakebusch,et al.  Rho GTPases in cancer: friend or foe? , 2019, Oncogene.

[23]  Wenlin Huang,et al.  ARHGEF19 interacts with BRAF to activate MAPK signaling during the tumorigenesis of non‐small cell lung cancer , 2018, International journal of cancer.

[24]  Jing Zhou,et al.  miR-503 regulates metastatic function through Rho guanine nucleotide exchanger factor 19 in hepatocellular carcinoma. , 2014, The Journal of surgical research.

[25]  M. Schymura,et al.  Identifying Risk Factors Associated with Subsequent Breast Cancer Diagnosis among Breast Cancer Survivors in New York State. , 2020, Journal of registry management.